Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq™ Cancer Hotspot Panel v.2.0

SAFIA A. MESSAOUDI1, NOURAH A. AL SHARHAN1, BANDAR ALHARTHI2, SARANYA R. BABU1, ABRAR B. ALSALEH1, ALANOUD M. ALASIRI1, MOURAD ASSIDI3,4, ABDELBASET BUHMEIDA3 and WASSIM Y. ALMAWI5

1Department of Forensic Science, Naif Arab University for Security Sciences, Riyadh 11452; 2Department of Surgery, King Fahad Medical City, Riyadh 12231; 3Center of Excellence in Genomic Medicine Research; 4Medical Laboratory Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia; 5Faculty of Sciences, El-Manar University, 1068 Tunis, Tunisia

Received October 13, 2021; Accepted January 12, 2022

DOI: 10.3892/br.2022.1509

Abstract. Next-Generation Sequencing allows for quick and precise sequencing of multiple genes concurrently. Recently, this technology has been employed for the identification of novel gene mutations responsible for disease manifestation among breast cancer (BC) patients, the most common type of cancer amongst Arabian women, and the major cause of disease-associated death in women worldwide. Genomic DNA was extracted from the peripheral blood of 32 Saudi Arabian BC patients with histologically confirmed invasive BC stages I-III and IV, as well from 32 healthy Saudi Arabian women using a QIAamp® DNA Mini Kit. The isolated DNA was quantified using a Qubit™ dsDNA BR Assay Kit with a Qubit 2.0 Fluorometer. Ion semiconductor sequencing technology with an Ion S5 System and AmpliSeq™ Cancer Hotspot Panel v2 were utilized to analyze ~2,800 mutations described in the Catalogue of Somatic Mutations in Cancer from 50 oncogenes and tumor suppressor genes. Ion Reporter Software v.5.6 was used to evaluate the genomic alterations in all the samples after alignment to the hg19 human reference genome. The results showed that out of the 50 genes, 26 mutations, including 17 (65%) missense point mutations (single nucleotide variants), and 9 (35%) frameshift (insertion/deletion) mutations, were identified in 11 genes across the cohort in 61 samples (95%). Mutations were predominantly focused on two genes, PIK3CA and TP53, in the BC genomes of the sample set. PIK3CA mutation, c.1173A>G located in exon 9, was identified in 15 patients (46.9%). The TP53 mutations detected were a missense mutation (c.215C>G) in 26 patients (86.70%) and 1 frameshift mutation (c.215_216insG) in 1 patient (3.33%), located within exon 3 and 5, respectively. This study revealed specific mutation profiles for every BC patient. Thus, the results showed that Ion Torrent DNA Sequencing technology may be a possible diagnostic and prognostic method for developing personalized therapy based on the patient's individual BC genome.

Introduction

Breast cancer (BC) is the most common malignancy in females and the second leading cause of cancer-related death after lung cancer worldwide (1). BC has a significant impact on a women's health (2), and its incidence rates have been steadily increasing in recent years in Arab-speaking communities, with a significant number of cases being diagnosed in the first instance at advanced stages of the disease (3). BC incidence varies widely globally (4), and its incidence amongst Saudi Arabian women has progressively increased (3). BC is a complex and multifactorial disease, and genetic, hormonal and environmental factors contribute to its pathogenesis (5). The interplay between the genetic background and the environment in BC development has been proposed, but with mixed results on the importance of each (6-8). Female sex, age and ethnicity are the strongest risk factors associated with increased incidence (9). In addition, obesity (10), age at first delivery of a child (11), early menarche/late menopause (12), ionizing radiation exposure (13), breastfeeding (14), past/current estrogen treatment (15), breast tissue density (16), smoking and alcohol consumption (17) and steroid hormone receptors (18) are all known risk factors of BC.

BC aggregates in families, and an estimated 5-10% of BC cases are hereditary in origin caused by a myriad of susceptibility genes, transmitted from parent to child (19). These include rare variants in BRCA1, BRCA2, PALB2, ATM and CHEK2 genes, which reportedly confer a moderate-high lifetime risk of the disease. Other variants of >70 loci, which were identified through genome-wide association study, and large-scale replication studies (20), were also reported to confer heightened risk of disease, though to varying extents.

While hereditary BC is linked to a well-established set of susceptibility genes, the exact contribution of these genes to
with no familial history of any cancer types served as the controls (mean age 49.1±11.0 years; median age, 47.5 years (age range, 35-71 years; IQR, 42.5-55)), were recruited into this retrospective case-controlled study from the blood bank (Table I). Demographic and clinical data of BC patients and control women were collected from the hospital records. All participants provided signed informed consent prior to inclusion in this study.

**Library preparation.** Manual library preparations were performed using an Ion AmpliSeq™ Cancer Hotspot Panel v.2, Ion Xpress barcoded adapters, and an Ion AmpliSeq Library Kit 2.0 (Thermo Fisher Scientific, Inc.). The panel consisted of 207 amplicons, covering ~20,000 bases surveying hotspot regions, including up to 2,855 COSMIC mutations in 50 oncogenes and tumor suppressor genes, all with known cancer associations. The genes included in this panel were: ABL1, AKTI, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAI1, GNAS, GNAQ, HNFA1, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53 and VHL.

Multiplex PCR was performed using 10 ng genomic DNA with a premixed primer pool and Ion AmpliSeq HiFi master mix (Ion AmpliSeq Library Kit 2.0). The amplicons were treated with 2 µl FuPa reagent to partially digest the primer sequences and phosphorylate the amplicons. Amplicons were ligated to adapters with the diluted barcodes of Ion Xpress Barcode Adapters kit (Thermo Fisher Scientific, Inc.). The adapter-ligated amplicons (library) were purified using the Agencourt AMPure XP reagent (Beckman Coulter, Inc.). Quantification of the final libraries was performed using an Ion Library TaqMan™ Quantitation Kit (Thermo Fisher Scientific, Inc.) on the Applied Biosystems® 7500 Real-Time PCR System, following the manufacturer's protocols.

**Patients and methods**

**Study subjects.** Ethical approval for the present study was obtained from the Ethics Committee of King Fahad Medical City (KFMC; Riyadh, Saudi Arabia; IRB approval no. FWA00018774), and the study was performed in accordance with the guidelines described in the Helsinki Declaration (37). A total of 32 Saudi Arabian patients with BC (mean age 48.5±8.2 years; median age 45 years [age range, 31-85 years; interquartile range (IQR) 42.5-55.5]), and with histologically confirmed invasive BC, were recruited from Medical Oncology Department, KFMC. None of the patients had a history of other cancer types and were not subjected to chemo-, radio or hormone therapy. In addition, 32 healthy Saudi women
(Thermo Fisher Scientific, Inc.), after alignment to the hg19 human reference genome. Of note, higher quality requirements for variant analysis and selection, high-quality SNVs and insertion/deletion variants were strictly followed in this study and were defined as: i) FILTER=PASS, ii) QUAL ≥100, iii) depth coverage ≥20X, and iv) variant fraction ≥20%. The sequencing data analysis using such approach yielded high-quality variants that did not necessarily require additional confirmatory testing (such as through Sanger sequencing validation) as recommended by Arteche-López group (38). Furthermore, the ‘bam’ files of each clinically actionable variant were carefully reviewed in order to provide additional confidence to the accuracy and reliability of the NGS calls.

Qualitative and quantitative data were analyzed using SPSS v.21 (IBM Corp.). Qualitative data are presented as the frequency and percentage of total, and these data were compared using a $\chi^2$ goodness-of-fit test, while continuous variables are presented as the mean ± SD, and were compared using an unpaired two-tailed Student's t-test. \( P<0.05 \) was considered to indicate a statistically significant difference.

## Results

### Study subjects

The clinical and demographic characteristics of the study subjects are summarized in Table I. Patients were clinically characterized in terms of tumor size, location, stage, histological classification and presence/absence of tumor markers, including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). In addition, age, body mass index (BMI), use of oral

| Characteristics | Healthy controls, n=32 | Patients BC, n=32 | P-value |
|-----------------|------------------------|------------------|---------|
| Mean age, years | 49.09±11.02            | 48.80±8.28       | 0.904d  |
| BMI, kg/m²     | 27.60±5.66             | 32.89±7.96       | 0.004ab |
| Oral contraceptives use |                  |                  | 0.5c    |
| Yes            | 19                     | 20               |         |
| No             | 13                     | 12               |         |
| Breastfeeding  |                        |                  | 0.011ae |
| Yes            | 19                     | 9                |         |
| No             | 13                     | 23               |         |
| Tumor size     |                        |                  |         |
| <2 cm          |                        | 4                |         |
| ≥2 cm          |                        | 28               |         |
| Tumor stage    |                        |                  |         |
| I              |                        | 3                |         |
| II             |                        | 11               |         |
| III            |                        | 13               |         |
| IV             |                        | 5                |         |
| Histological classification |                  |                  |         |
| IDC            |                        | 29               |         |
| ILC            |                        | 2                |         |
| DCIS           |                        | 1                |         |
| Tumor location |                        |                  |         |
| Left           |                        | 28               |         |
| Right          |                        | 4                |         |
| ER status      |                        |                  |         |
| ER+            |                        | 23               |         |
| ER-            |                        | 9                |         |
| PR status      |                        |                  |         |
| PR+            |                        | 21               |         |
| PR-            |                        | 11               |         |
| HER2 status    |                        |                  |         |
| HER2+          |                        | 13               |         |
| HER2-          |                        | 19               |         |

\( ^aP<0.05, ^bP<0.01, ^c\text{Mean ± standard deviation}, ^d\text{Unpaired Student's t-test}, ^e\text{\( \chi^2 \) test}. \) HER2, Human epidermal growth factor receptor; ER, Estrogen receptor; PR, Progesterone receptor; DCIS, Ductal carcinoma in situ; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma.
contraception and breastfeeding were compared between the two groups. No statistically significant differences were noted between patients and controls regarding mean age (P=0.90), and oral contraceptive use (P=0.50). However, a significant difference was noted between BC patients and healthy subjects for mean BMI, which was higher in patients compared with the control group (P=0.004), and breastfeeding (P=0.011), which was higher in the healthy control group.

Invasive ductal carcinoma of no specific type (n=29, 90.6%) was the predominant histological type of primary tumor, followed by invasive lobular carcinoma (n=2, 6.3%), and ductal carcinoma in situ (n=1, 3.1%). The majority of cases were stage III (n=13, 40.6%) and stage II (n=11, 34.4%), whereas stage I (n=3, 9.3%) and stage IV (n=5, 15.6%) were less common. In addition, 4 patients (12.5%) had ER+, PR+, HER2+ tumors; 21 patients (65.6%) had ER+, and/or PR+, HER2+ tumors, 4 patients (12.5%) had ER-, PR-, HER2+ tumors, and 3 patients (9.4%) had triple-negative (ER-, PR-, HER2+) tumors.

Somatic mutations. There were only three unclassified samples, two from patients (sample #2 and sample #13) and 1 from a control individual (sample #4) that did not possess any identified mutations (Fig. 1). The observed mutations were detected with varied frequencies across BC patients (Table II) and healthy controls (Table III); 26 mutations, including 17 (65%) missense point mutations (SNV), and 9 (35%) frameshift (insertion/deletion) mutations in 11 genes (out of 50); TP53, PIK3CA, KDR, KIT, ATM, HRA5, ERBB2, FGFR3, GNAQ, APC and JAK3 (Fig. 2) across the cohort in the 61 samples (95%).

Amongst BC patients, 27 patients (84.8%) were positive for ≥1 somatic mutation, compared with 17 control subjects (53.1%) (Fig. 1). The most frequently observed concurrent mutations were some combination of c.215C>G (TP53), c.1173A>G (PIK3CA), c.1416A>T (KDR) and c.1621A>C (KIT) in patients (Fig. 3A), and c.215C>G (TP53), c.1173A>G (PIK3CA) and c.1416A>T (KDR) in healthy controls (Fig. 3B).

The site of the most frequent mutations within TP53 and PIK3CA differed between samples. The most common TP53 mutation detected was a missense mutation (c.215C>G) in 26 patients (86.70%), with only 1 frameshift mutation (c.215_216insG) identified in 1 patient (3.33%). The most common PIK3CA mutation detected was c.1173A>G, located in exon 9, and was identified in 15 (50%) patients.

Table IV summarizes the distribution of the most frequent missense mutations in TP53 and PIK3CA (c.215C>G and c.1173A>G, respectively), between patients and healthy control samples. A significant difference (P=0.020) was observed in the frequency of c.215C>G (Pro72Arg), which was higher in patients (0.87) than in controls (0.61). Similarly, a significant difference was observed in the frequency of c.1173A>G (Pro72Arg) (P=0.041) that was higher in patients (0.53) compared with the healthy control participants (0.25).

A unique mutational status was identified for every BC patient except for patients #8, #10, #18, and #20 (Table II).

Discussion

BC is the most common type of cancer amongst Arabian women, and the major cause of disease-associated mortality in women worldwide (39). In the Middle East, Arabian women face a significantly higher risk of mortality, as the cancer is often diagnosed at a later stage in disease progression (40-45).

Current efforts to manage BC include on improving prevention, diagnosis and an increased armamentarium of effective treatment choices for patients with BC (46). Due to the heterogeneity of BC and the interactions between genetic and environmental factors, each patient's tumor possibly exhibits an unique gene mutation profile (47). By profiling an individual's cancer genome, it becomes possible to differentiate the oncogenic mechanisms that regulate cancer and, therefore, the genetic biomarkers that may be specifically associated with the disease state (5).

In this study, massively parallel sequencing was performed to identify frequent mutations in 32 BC Saudi Arabian patients and 32 healthy controls using Ion Torrent sequencing technology.

In this study, 32 BC patients were clinically characterized in terms of tumor size, location, stage, histological classification, and the presence or absence of tumor markers such as ER, PR, and HER2. In addition, four common risk factors, including age, BMI, oral contraceptives use and breastfeeding, were also evaluated and compared between healthy controls and BC patients. The statistical analysis showed no significant difference in the mean age between BC patients and healthy controls as the two study groups were already age matched.

BMI was significantly higher in BC patients compared with the healthy control group. This finding is in agreement with several reports, highlighting BMI as one of the most important risk factors for the BC (48,49). Chronic low-levels of inflammation that are usually observed in obese people can lead to BC through the increased likelihood of DNA damage (50). Additionally, fat cells can produce an excess amount of estrogen and adipokines, which can stimulate cell growth, as observed in BC (49,51). Similarly, a significant difference was observed for breastfeeding, which was higher in control group compared to the BC patients group, supporting the previously published literature linking breastfeeding to reduced BC risk (52).

PIK3CA and TP53 are the most frequently mutated genes, and harbor most of the mutations in this cohort. The p53 tumor suppressor gene, located on chromosome 17p13,
Table II. Mutational status of breast cancer patient samples analyzed using the Ion AmpliSeq™ Cancer Hotspot Panel v2.

| No. | Tumor histologic type | Stage | Hormone receptor status | Genes | Mutations detected | Effect | Amino acid change |
|-----|-----------------------|-------|-------------------------|-------|---------------------|--------|------------------|
| 1   | IDC                   | III   | HER2⁺ ER⁺ PR⁺           | PIK3CA KDR GNAQ TP53 | c.1173A>G c.1416A>T c.625C>A c.215C>G | Missense | p.Ile391Met p.Gln472His p.Gln209Lys p.Pro72Arg |
| 2   |                       |       |                         | HRAS  | c.84_85insT c.80_81insC | Frameshift | p.Val29fs, p.Val29fs |
| 3   | IDC                   | IV    | HER2⁺ ER⁻ PR⁻           | PIK3CA KDR HRAS TP53 JAK3 | c.1173A>G c.1416A>T c.84_85insT c.80_81insC c.394C>A | Missense Missense Missense Missense | p.Ile391Met p.Gln472His p.Pro72Arg p.Pro132Thr |
| 4   | IDC                   | III   | HER2⁺ ER⁺ PR⁺           | PIK3CA KDR TP53 | c.1173A>G c.1416A>T c.215C>G | Missense | p.Ile391Met p.Gln472His p.Pro72Arg |
| 5   | IDC                   | II    | HER2⁺ ER⁺ PR⁺           | HRAS  | c.80_81insC | Frameshift | p.Pro72Arg |
| 6   | IDC                   | III   | HER2⁺ ER⁻ PR⁻           | KIT    | c.1621A>C | Missense | p.Met541Leu |
| 7   | IDC                   | III   | HER2⁺ ER⁻ PR⁻           | HRAS  | c.1416A>T | Missense | p.Gln472His |
| 8   | IDC                   | II    | HER2⁺ ER⁺ PR⁺           | TP53   | c.215C>G | Missense | p.Pro72Arg |
| 9   | IDC                   | II    | HER2⁺ ER⁺ PR⁺           | KIT    | c.1416A>T | Missense | p.Pro132Thr |
| 10  | IDC                   | II    | HER2⁺ ER⁺ PR⁺           | HRAS  | c.80_81insC | Frameshift | p.Pro72Arg |
| 11  | IDC                   | IV    | HER2⁺ ER⁻ PR⁻           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 12  | DCIS                  | III   | HER2⁺ ER⁻ PR⁻           | KIT    | c.1416A>T | Missense | p.Gln472His |
| 13  | IDC                   | I     | HER2⁺ ER⁺ PR⁻           | TP53   | c.215C>G | Missense | p.Pro72Arg |
| 14  | IDC                   | III   | HER2⁺ ER⁺ PR⁺           | ATM    | c.2525C>G | Missense | p.Thr842Ser |
| 15  | IDC                   | IV    | HER2⁺ ER⁺ PR⁺           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 16  | IDC                   | IV    | HER2⁺ ER⁺ PR⁺           | APC    | c.3920T>A c.3920T>T | Frameshift | p.Ile1307Lys p.Ile1307Lys |
| 17  | IDC                   | IV    | HER2⁺ ER⁺ PR⁺           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 18  | IDC                   | II    | HER2⁺ ER⁺ PR⁻           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 19  | IDC                   | II    | HER2⁺ ER⁺ PR⁻           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 20  | IDC                   | II    | HER2⁺ ER⁺ PR⁻           | PIK3CA | c.1173A>G | Missense | p.Ile391Met |
| 21  | ILC                   | I     | HER2⁺ ER⁺ PR⁺           | FGFR3  | c.2389G>C | Missense | p.Ala797Pro |
| 22  |                       |       |                         | ATM    | c.7313C>T | Missense | p.Thr2438Ile |
| 23  |                       |       |                         | TP53   | c.215C>G | Missense | p.Pro72Arg |
is 20 kb long, encompassing 11 exons encoding a 53 kDa phosphoprotein (53). In the present study the detected mutations in this gene were 1 missense mutations (c.215C>G) in 26 patients (86.70%) and 1 frameshift mutation (c.215_216insG) in 1 patient (3.33%). These results are in agreement with the current release of the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/), which also shows that all TP53 mutations were missense mutations in the coding region (54). The detected mutations were located within exons 3 and 5, encoding the Proline-rich domain, which plays a role in p53-mediated apoptosis and in the DNA-binding and oligomerization domain. These regions are required for interactions with FBX042, HIPK1 and AXIN1, the DNA major groove, and a domain containing a nuclear export signal (46,55,56). Dysfunction of p53 can cause defective DNA replication and malignant transformation, common in dysplasia's of BC (53). The p53 gene exhibits several genetic alterations in patients with BC (57). This highlights the need to administer effective treatments such as cell-cycle inhibitors and combinatorial target therapies against the wide range of TP53 mutations.

In the current study, the high TP53 mutation rate in the cohort could be explained by the high number of ER+ cases, given that 67% of the observed TP53 mutations occurred in the ER+ tumors. ER status is tightly associated with the molecular subtypes, and a significantly higher TP53 mutation rate was demonstrated in the basal-like subtype, mainly ER-, and HER2-enriched (both ER- and ER+) tumors compared to the primarily ER+ luminal type (56,58). A recent study by Bai et al (59) conducted in 2021 using NGS to detect TP53 mutations in the cell free DNA in Chinese metastatic BC (MBC) patients indicated that TP53 mutations could be used as a prognostic marker for worse outcomes in MBC and for the response of adjuvant endocrine therapy. TP53-mutated MBC patients had a significantly worse outcome than TP53 wild-type patients, especially those in the HR+/HER2- and triple-negative BC (TNBC) cohorts. TP53 mutations were also associated with endocrine resistance (59).

In the present study TP53 mutations were not associated with HER2+ tumors, which is comparable to the previously published research. TP53 mutation status was an independent predictive factor of survival especially in HR+/HER2+ and TNBC cohorts, but not in the HER2+ cohort (59,60).

In the present study, the somatic TP53 mutation c.215C>G p.(Pro72Arg) was the most frequently detected mutation in all BC patients, particularly those with Stage III BC. A previous
Table III. Mutational status of healthy control samples analyzed using the Ion AmpliSeq™ Cancer Hotspot Panel v2.

| No. | Genes     | Mutations detected            | Effect    | Amino acid change |
|-----|-----------|--------------------------------|-----------|-------------------|
| 1   | KDR       | c.1416A>T                      | Missense  | p.Gln472His       |
| 2   | HRAS      | c.80_81insC                    | Frameshift| p.Val29fs         |
| 3   | ERBB2     | c.2380G>T                      | Missense  | p.Val794Leu       |
| 4   | KDR       | c.1416A>T                      | Missense  | p.Gln472His       |
| 5   | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
| 6   | TP53      | c.209_215delCTCCCCCinsTCCCCCG  | Frameshift| p.Ala70_Pro72delinsValProArg |
| 7   | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
| 8   | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 9   | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
| 10  | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
| 11  | APC       | c.3920T>A                      | Missense  | p.Ile1307Lys      |
| 12  | ATM       | c.1811delC                     | Frameshift| p.Pro604fs        |
| 13  | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
| 14  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 15  | KIT       | c.1621A>C                      | Missense  | p.Met541Leu       |
| 16  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 17  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 18  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 19  | ATM       | c.1416A>T                      | Missense  | p.Gln472His       |
| 20  | KDR       | c.1416A>T                      | Missense  | p.Gln472His       |
| 21  | TP53      | c.1416A>T                      | Missense  | p.Gln472His       |
| 22  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 23  | KIT       | c.1621A>C                      | Missense  | p.Met541Leu       |
| 24  | ATM       | c.2572T>C                      | Missense  | p.Phe858Leu       |
| 25  | TP53      | c.2572T>C                      | Missense  | p.Phe858Leu       |
| 26  | KIT       | c.1621A>C                      | Missense  | p.Met541Leu       |
| 27  | KDR       | c.1416A>T                      | Missense  | p.Gln472His       |
| 28  | PIK3CA    | c.1173A>G                      | Missense  | p.Ile391Met       |
| 29  | KIT       | c.1621A>C                      | Missense  | p.Met541Leu       |
| 30  | ATM       | c.2572T>C                      | Missense  | p.Phe858Leu       |
| 31  | TP53      | c.2572T>C                      | Missense  | p.Phe858Leu       |
| 32  | KDR       | c.1416A>T                      | Missense  | p.Gln472His       |
| 33  | TP53      | c.215C>G                       | Missense  | p.Pro72Arg        |
study showed that TP53 mutation NM_000546.5:c.824G>A p.(Cys275Tyr) was the most common mutation detected in 82 patients with Stage I-III BC who underwent NGS using tissue and blood samples, and they showed that TP53 pathogenic somatic mutations were associated with an 8-fold risk of recurrence in the univariate Cox regression analysis (61). The same study showed that the coexistence of TP53 and PIK3CA mutations was a common finding in BC patients (61).

PIK3CA mutation (c.1173A>G) and p.(Ile391Met) located in exon 9, was identified in 15 (50%) patients. This exon encodes the helical domain, and mutations, represented by single amino acid substitutions, in this domain are associated with increased lipid kinase activity, and thus induce oncogenic transformation (62,63).

The PI3K pathway has been identified as a major player in cancer development and progression (62-66). PI3K is a heterodimeric enzyme composed of a p110α catalytic subunit encoded by the PIK3CA gene and a p85 regulatory subunit encoded by the PIK3R1 gene (67). In the present study, 47% of the BC patients were carriers of PIK3CA mutations. This result corroborates the findings of the previous work, reporting that PIK3CA mutations occur in 20-40% of BC and ≈30% of tumors of the prostate, cervix and endometrium (68,69). Several studies have suggested that PIK3CA mutations are more frequent in ER+ and HER2+ BC cases (68,69). Accordingly, the low mutation rate can be explained by a bias in the subtype distribution of the cohort. In the present study, 2 out of 5 (40%) of the PIK3CA mutations occurred in ER+ primary tumors. The small size of the cohort may have influenced this distribution. Martínez-Sáez et al (70) showed that 28% of PIK3CA mutations identified in circulating tumor DNA (ctDNA) in 48 patients with advanced HR+HER2- BC were not part of the therascreen PIK3CA test (QIAGEN GmbH), a FDA approved kit used to select patients who possessed PIK3CA mutations in tumor tissue specimens and/or in circulating tumor DNA (ctDNA) isolated from plasma specimens (71). Therascreen PIK3CA detects 11 PIK3CA hotspot mutations, mostly found in exons 9 and 20 (71).

It is important to remember that only a subset of genes was examined in the present study, and that for a deeper understanding of the mutational profiles of BC patients, considerably more extensive sequencing is required. The hotspot panel was not specifically developed for BC, and it includes areas

| No. | Genes | Mutations detected | Effect | Amino acid change |
|-----|-------|--------------------|--------|-------------------|
| 24  | PIK3CA| c.1173A>G          | Missense| p.Ile391Met        |
|     | APC   | c.3920T>A          | Missense| p.Ile1307Lys       |
|     | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 25  | PIK3CA| c.1173A>G          | Missense| p.Ile391Met        |
|     | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 26  | KIT   | c.1621A>C          | Missense| p.Met541Leu        |
|     | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 27  | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 28  | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 29  | PIK3CA| c.1173A>G          | Missense| p.Ile391Met        |
|     | APC   | c.3920delT         | Frameshift| p.Ile1307fs      |
|     | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 30  | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 31  | TP53  | c.215C>G           | Missense| p.Pro72Arg         |
| 32  | TP53  | c.215C>G           | Missense| p.Pro72Arg         |

Del, deletion; ins, insertion; fs, frameshift.

| Gene | Mutation | Amino acid change | Chromosome Exon | NCBI 1000 Genomes Browser ID | Variant frequency in the patients | Variant frequency in the healthy controls | P-valueb |
|------|----------|-------------------|-----------------|-----------------------------|----------------------------------|------------------------------------------|-----------|
| TP53 | c.215C>G | p.Pro72Arg        | 17 3            | rs1042522                   | 0.87                             | 0.61                                     | 0.020*    |
| PIK3CA| c.1173A>G| p.Ile391Met       | 3 9             | rs2230461                   | 0.53                             | 0.25                                     | 0.041*    |

*p<0.05. bχ² test.
and genes that are more commonly mutated in other cancer types (72).

Recently, Hempel et al (73) utilized a wide NGS panel to investigate 41 MBC samples and found that PIK3CA mutations appear in 34% of the patients. A recent study reported that 22% of the total population and 28% of patients with HR+ BC have a PIK3CA mutation (74). Further research using a large NGS panel targeting 1,021 genes in 193 MBC samples by Tang et al (75) detected 36 (18.7%) mutations in the kinase domain and 26 (13.5%) substitutions in the helical domain, with 10 (5.2%) additional alterations distributed in the remaining PIK3CA sequence.

PIK3CA mutations in the ctDNA of patients with BC have also been reported (76). Board et al (77) was able to detect
PIK3CA mutations in the vast majority (80%) of ctDNA samples from PIK3CA-mutated MBC, but not in early BC (78).

In conclusion, the results of this investigation showed that Ion Torrent DNA Sequencing technology using AmpliSeq Cancer Hotspot Panel v2 was found to be a suitable method to perform molecular characterization of the genotype of BC patients and healthy controls using peripheral blood samples. The present study revealed specific mutational profiles for every BC patient; for this reason, it may be possible to improve diagnosis and prognosis, and recommend...

Figure 2. Heat maps displaying the combination of the different mutations in the 32 BC patients (A and B) and the 32 healthy controls (C and D).
personalized treatments for each BC patient based on the mutational profile. The primary benefits of NGS are that it allows for the identification of multiple mutations at the same time, eliminating the need for sequential individual tests. Therefore, this technique could be routinely implemented in cancer diagnosis, as it can precisely identify fusions, SNPs, copy number variants, and insertion/deletions. Additionally, confirmation of NGS variants must be carefully investigated and validated through Sanger sequencing to avoid false positive outcomes. The results of the present study add to the existing body of knowledge and practice in the diagnosis and treatment of BC patients.

Acknowledgements

Not applicable.

Funding

This work was supported by Naif Arab University for Security Sciences, Kingdom of Saudi Arabia.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

SAM conceived the study, curated the data, analyzed the data, performed the experiments and wrote and reviewed the manuscript. NAAS, BA and SRB contributed to the design of the study, performed the experiments and drafted the manuscript. ABA and AMA performed the experiments and contributed to data analysis and interpretation. MA, AB and WYA conceived the study, performed data interpretation, and wrote and critically reviewed the manuscript. SAM, MA and AB confirm the authenticity of all the raw data. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval for this study was obtained from the Ethics Committee of King Fahad Medical City (KFMC; Riyadh, Saudi Arabia; IRB approval no. FWA00018774), and the study was performed in accordance with the guidelines described in the Helsinki Declaration. All participants provided signed informed consent prior to inclusion in this study.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Stewart BW and Wild CP (eds): World Cancer Report 2014. International Agency for Research on Cancer, WHO, 2014.
2. Testa U, Castelli G and Pelosi E: Breast cancer: A molecularly heterogeneous disease needing subtype-specific treatments. Med Sci (Basel) 8: 18, 2020.
3. Almutlaq BA, Almuazzi RF, Almuhayfir AA, Alfouzan AM, Alshammari BT, AlAnzi HS and Ahmed HG: Breast cancer in Saudi Arabia and its possible risk factors. J Cancer Policy 12: 83-89, 2017.
4. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin 68: 7-30, 2018.
5. Zhang J, Späth SS, Marjani SL, Zhang W and Pan X: Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precis Clin Med 1: 29-48, 2018.
6. Fasching PA, Ekici AB, Adamietz BR, Wachter DL, Hein A, Bayer CM, Häberle L, Loehberg CR, Jud SM, Heusinger K, et al: Breast cancer risk-genes, environment and clinics. Geburtsh Frauenheilk 71: 1056-1066, 2011.
7. Rudolph A, Chang-Claude J and Schmidt MK: Gene-environment interaction and risk of breast cancer. Br J Cancer 114: 125-133, 2016.
8. Hiatt RA, Haslam SZ and Osuch J: Breast Cancer and the Environment Research Centers: The breast cancer and the environment research centers: Transdisciplinary research on the role of the environment in breast cancer etiology. Environ Health Perspect 117: 1814-1822, 2009.
9. Winters S, Martin C, Murphy D and Shokar NK: Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci 151: 1-32, 2017.
10. Parkin DM and Boyd L: 8. Cancers attributable to overweight and obesity in the UK in 2010. Br J Cancer 105 (Suppl 2): S34-S37, 2011.
11. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O’Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, et al: Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Ann Intern Med 156: 635-648, 2012.
12. Collaborative Group on Hormonal Factors in Breast Cancer: Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 13: 1141-1151, 2012.

13. Fega C: Occupational exposure and risk of breast cancer. Biomed Rep 4: 282-292, 2016.

14. Elkim N, Al-Tweigeri T, Ajarim D, Al-Zahrani A, Amer SM and Aboussoukhra A: Obesity is a significant risk factor for breast cancer in Arab women. BMC Cancer 14: 788, 2014.

15. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalex M, Bajic-Radisic V, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691, 2009.

16. McCormack VA and dos Santos Silva I: Breast density and parenchymal patterns of breast cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 1159-1169, 2006.

17. Druesne-Pecollo N, Touvier M, Barrandon E, Chan DS, Norat T, Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Elkum N, Al-Tweigeri T, Ajarim D, Al-Zahrani A, Amer SM, Aguayo-Capelli D, Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Forster EH, Shoemaker ML, Barrera CM, O'Neil ME, Verma AB, Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Arteche-López A, Avila-Fernández A, Romero R, Rivero-Alvarez R, López-Martínez A, Gómez-Pardo A, Vélez-Monsalve C, Gallego-Merlo J, García-Vara I, Almoguera B, et al: Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. Sci Rep 11: 5697, 2021.

18. Abderrahman B and Jordan VC: Rethinking extended adjuvant chemotherapy in breast cancer: First take home messages. Curr Opin Oncol 24: 597-604, 2012.

19. Ma R, Gong J and Jiang X: Novel applications of next generation sequencing in breast cancer treatment. Cancer Genes Dis 4: 149-153, 2017.

20. Shrestha B and Dunn L: The declaration of Helsinki on medical research involving human subjects: A review of seventh revision. J Nepal Health Res Coun 17: 548-552, 2020.

21. Arteche-López A, Avila-Fernández A, Romero R, Rivero-Alvarez R, López-Martínez A, Gómez-Pardo A, Vélez-Monsalve C, Gallego-Merlo J, García-Vara I, Almoguera B, et al: Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. Sci Rep 11: 5697, 2021.

22. Donnelly TT, Khater AH, Al-Bader SB, Al Kuwari MG, Malik M, Al-Meer N, Singh R and Fung T: Factors that influence awareness of breast cancer screening among Arab women in Qatar: Results from a cross sectional survey. Asian Pac J Cancer Prev 15: 2015-2019, 2014.

23. Azza F and Cohen M: Health beliefs and rates of breast cancer screening among Arab women. J Womens Health (Larchmt) 15: 520-530, 2006.

24. Baron-Epel O, Friedman N and Lernau O: Reducing disparities in mammography-use in a multicultural population in Israel. Int J Equity Health 18: 19, 2019.

25. Bener A, Ayub H, Kakil R and Ibrahim W: Patterns of cancer incidence among the population of Qatar: A worldwide comparative study. Asian Pac J Cancer Prev 9: 19-24, 2008.

26. Najjar H and Easson AM: Breast cancer diagnosis and surgical treatment in breast cancer in Arab nations. Int J Surg 8: 448-452, 2010.

27. Sokolove V, Marie S and Moran O: Beliefs, recommendations and intentions are important explanatory factors of mammography screening behavior among Muslim Arab women in Israel. Health Educ Res 22: 665-676, 2007.

28. Tarabeia J, Baron-Epel O, Barchana M, Lipshitz I, Irahi A, Fisher Y and Green MS: A comparison of trends in incidence and mortality rates of breast cancer, incidence to mortality ratio and stage at diagnosis between Arab and Jewish women in Israel, 1979-2002. Eur J Cancer Prev 16: 36-42, 2007.

29. Bai X, Zhang E, Ye H, Nandakumar V, Wang Z, Chen L, Tani C, Li J, Li H, Zhang W, et al: PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. PLoS One 9: e99306, 2014.

30. Cho SH, Jeon J and Kim SI: Personalized medicine in breast cancer: A systematic review. J Breast Cancer 15: 265-272, 2012.

31. van den Brandt PA, Spiegelman D, Vaillant FS, Adami HO, Besson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi LH, et al: Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. Sci Rep 11: 5697, 2021.

32. Seo BR, Bhardwaj P, Choi S, Gonzalez J, Andresen Eguiluz RC, Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, Arteche-López A, Avila-Fernández A, Romero R, Rivero-Alvarez R, López-Martínez A, Gómez-Pardo A, Vélez-Monsalve C, Gallego-Merlo J, García-Vara I, Almoguera B, et al: Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. Sci Rep 11: 5697, 2021.

33. Smith NG, Gyanchandani R, Shah OS, Gurdé GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kuta K, et al: Targeted mutation detection in breast cancer using MammaSeq™. J Breast Cancer Res 21: 22, 2019.

34. Desmedt C, Vooi T, Sotiriou C and Campbell PF: Next-generation sequencing in breast cancer: First take home messages. Curr Opin Oncol 24: 597-604, 2012.

35. Ma R, Gong J and Jiang X: Novel applications of next generation sequencing in breast cancer treatment. Cancer Genes Dis 4: 149-153, 2017.

36. Shrestha B and Dunn L: The declaration of Helsinki on medical research involving human subjects: A review of seventh revision. J Nepal Health Res Coun 17: 548-552, 2020.

37. Arteche-López A, Avila-Fernández A, Romero R, Rivero-Alvarez R, López-Martínez A, Gómez-Pardo A, Vélez-Monsalve C, Gallego-Merlo J, García-Vara I, Almoguera B, et al: Sanger sequencing is no longer always necessary based on a single-center validation of 1109 NGS variants in 825 clinical exomes. Sci Rep 11: 5697, 2021.

38. Donnelly TT, Khater AH, Al-Bader SB, Al Kuwari MG, Malik M, Al-Meer N, Singh R and Fung T: Factors that influence awareness of breast cancer screening among Arab women in Qatar: Results from a cross sectional survey. Asian Pac J Cancer Prev 15: 2015-2019, 2014.
57. Ko LJ and Prives C: p53: Puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.

58. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.

59. Bai H, Yu J, Jia S, Liu X, Liang X and Li H: Prognostic value of the TP53 mutation location in metastatic breast cancer as detected by next-generation sequencing. Cancer Manag Res 13: 3303-3316, 2021.

60. Ren J, Wang B and Li J: Integrating proteomic and phospho-proteomic data for pathway analysis in breast cancer. BMC Syst Biol 12 (Suppl 8): S130, 2018.

61. Andrikopoulou A, Terpos E, Chatzinikolaou S, Apostolidou K, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA and Zagouri F: TP53 mutations determined by targeted NGS in breast cancer: A case-control study. Oncotarget 12: 2206-2214, 2021.

62. Bader AG, Kang S and Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479, 2006.

63. Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase and cancer. Proc Natl Acad Sci USA 102: 802-807, 2005.

64. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.

65. Noorolyai S, Shajari N, Baghbani E, Sadreddini S and Baradaran B: The relation between PI3K/AKT signalling pathway and cancer. Gene 698: 120-128, 2019.

66. Janku F, Yap TA and Meric-Bernstam F: Targeting the PI3K pathway in cancer: Are we making headway? Nat Rev Clin Oncol 15: 273-291, 2018.

67. Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.

68. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, Li E, Sadreddini S and Baradaran B: The relation between PI3K/AKT signalling pathway and cancer. Gene 698: 120-128, 2019.

69. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, et al: PIK3CA mutations impact on survival in breast cancer patients and in ER+, PR+ and ERBB2-based subgroups. Breast Cancer Res 14: R28, 2012.

70. Sas T, Kato T, Yamada K, Takahashi T, Umemura K, Sato T, Ohsawa M, Ohnishi K, et al: PIK3CA mutations as a molecular target for hormone receptor-positive, HER2-negative metastatic breast cancer. Front Oncol 11: 644737, 2021.

71. QIAGEN Manchester, Ltd. therascreen® PIK3CA RGQ PCR Kit Instructions for Use (Handbook), 2019 (cited 2022 16 January); Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf19/P190001C.pdf.